Lucid Diagnostics Inc. (LUCD)
| Previous Close | 0.8900 |
| Open | 0.8900 |
| Bid | 0.8359 x 200 |
| Ask | 0.9272 x 100 |
| Day's Range | 0.8800 - 0.8999 |
| 52 Week Range | 0.6300 - 1.8500 |
| Volume | |
| Avg. Volume | 225,919 |
| Market Cap | 46.163M |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
PAVmed Provides Business Update and First Quarter 2024 Financial Results
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three months ended March 31, 2024.
- PR Newswire
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended March 31, 2024.
- PR Newswire
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), announced that the legacy EsophaCap sponge-on-a-string (SOS) esophageal cell collection device, which it briefly supplied to third-party institutions for their own research studies, has been subjected to a Class II FDA recall due to two serious device failures reported in a recent publica
